Danish pension funds under pressure to invest in domestic markets

The Danish government is putting pressure on the country’s DKr5.5tn (€737bn) pensions industry to invest more in the domestic ...

BMO Raises Novo Nordisk A/S (NVO) Price Target but Flags Prescription Pressures

Novo Nordisk A/S (NYSE:NVO) is among the most profitable healthcare stocks to buy. On January 26, BMO Capital lifted the ...

The disruptive force of weight loss drugs: How GLP-1s do more than shed pounds

There’s no denying the popularity of weight-loss drugs in the United States, with one in eight adults relying on GLP-1s to ...

Should You Buy Novo Nordisk Stock on Oral Wegovy's Strong Launch?

However, Novo Nordisk has a plan to get things back on track, and the company's oral Wegovy is part of that strategy. In ...

Novo Nordisk: Momentum Meets Headwinds Before Earnings (Upgrade)

Novo Nordisk A/S gains in GLP-1 obesity pills with strong U.S. marketing. Click for this NVO stock update and a preview of ...

Danish Play Explores Novo Nordisk's Surge in Weight Loss Market

"Everybody has some relationship to Novo Nordisk and everybody's pension has stocks in Novo," said Sebastian Henry ...

AstraZeneca strikes multibillion-dollar obesity deal with China’s CSPC Pharmaceuticals

The agreement, to gain rights to a portfolio of early-stage experimental obesity and diabetes drugs is the largest of its type in terms of total potential value.

AstraZeneca Strikes Multibillion-Dollar Obesity Deal With China's CSPC Pharmaceuticals — 2nd Update

AstraZeneca said it entered into a collaboration agreement with China's CSPC Pharmaceuticals to gain rights to a portfolio of ...

Novo Nordisk's China President Zhou to step down in March

The longtime head of Novo Nordisk's China business will leave the company, the Danish drugmaker said on Friday, as it ...